University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment
At University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD in Sofia, research in diagnostic imaging focuses on improving the performance and safety of magnetic resonance imaging contrast agents. These studies are designed to support better detection of central nervous system and non-central nervous system conditions, while also expanding knowledge in pediatric imaging.
- Evaluating new contrast enhancement approaches for MRI-based diagnosis
- Studying imaging support for central nervous system pathology and other body regions
- Assessing how contrast agents perform in children undergoing CE-MRI
The overall aim is to test whether newer imaging agents can match or improve the effectiveness of established options while maintaining a strong safety profile.
Musculoskeletal Diseases
Clinical research in musculoskeletal diseases at this site includes work on psoriatic arthritis, with a focus on finding better ways to control symptoms and improve patient outcomes. This area reflects the hospital’s broader interest in both treatment effectiveness and patient-centered care.
- Testing a new therapy for psoriatic arthritis
- Measuring improvement in joint and inflammation-related symptoms
- Comparing treatment benefit against placebo to understand effectiveness
These trials aim to determine whether emerging treatments can offer meaningful relief for people living with inflammatory joint disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 195 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 192 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1Novartis Pharma AG3active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG7trials
lock +19 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD
lock Showing 1 of 94 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 195 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 7 | Unknown | 2019-03-22 | 2025-10-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.